

Image
1645

TRANSMITTAL LETTER			Case No. 10709/47
Serial No. 10/630,180	Filing Date July 30, 2003	Examiner	Group Art Unit 1645
Inventor(s) Wei, et al.			
Title of Invention Method For Multiple Chemokine Receptor Screening For Antagonists Using RAM Assay			

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Information Disclosure Statement (in duplicate), International Search Report, Form PTO-1449, Copies of Cited References A4, A6-8, A11-13, A17-18, and A20, Postcard Receipt.

- ☒ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		or	Other Than Small Entity	
Rate	Add'l Fee		Rate	Add'l Fee
x \$9 =			x \$18 =	
x 43 =			x \$86 =	
+ \$145 =			+ \$290 =	
Total add'l fee	\$		Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ _____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Magdalena O. Cilella
Magdalena O. Cilella, Ph.D.
Limited Recognition Certificate Previously Filed on July 30, 2003
Agent of Attorney for Applicant
Customer No. 00757 - Brinks Hofer Gilson Lione

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 27, 2003.

Date: 10/27/03

Signature: Magdalena O. Cilella



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

October 27, 2003

Date of Deposit

Magdalena O. Cilella, Ph.D.

Name of Applicant, Assignee or
Registered Representative

Magdalena Cilella

Signature

October 27, 2003

Date of Signature

Our Case No.: 10709/47

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wei, et al.

Serial No.: 10/630,180

Filing Date: July 30, 2003

For: METHOD FOR MULTIPLE
CHEMOKINE RECEPTOR
SCREENING FOR ANTAGONISTS
USING RAM ASSAY

Examiner:

Group Art Unit No.: 1645

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record.

This application is a continuation-in-part application of U.S. Serial No. 10/154,399, filed May 22, 2002 and is relied upon for an earlier filing dated under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d), only copies of documents not previously cited and submitted to the Patent and Trademark Office in the prior application Serial No. 10/154,399, denoted by an asterisk ("*"), are enclosed for the convenience of the Examiner.

The references now cited are the following:

U.S. Patent Documents:

6,451,522 B2 LaRosa, G.
2003/0166143 A1 Klein CA, et al.
4,816,567

Other Art:

*Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, *et al.* 1987. Current protocols in molecular biology. John Wiley & Sons, New York.

Bacon, K.B., R.D. Camp, F.M. Cunningham, and P.M. Woollard. 1988. Contrasting in vitro lymphocyte chemotactic activity of the hydroxyl enantiomers of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. *Br J Pharmacol.* 95:966-74.

*Baggiolini et al., *Annu. Rev. Immunol*, 15: 675-705 (1997)

*Baggiolini et al., *Advances in Immunology*, 55:97-179 (1994)

*Deng, et al., *Nature*, 381:661-666 (1996)

Ellington, A.D., and J.W. Szostak. 1990. In vitro selection of RNA molecules that bind specific ligands. *Nature.* 346:818-22.

Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, *et al.* 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. *Cell.* 99:23-33.

*Horuk, Trends Pharm. Sci., 15:159-165 (1994)

*Jayasena, S.D. 1999. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. *Clin Chem.* 45:1628-50.

*Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger, *et al.* 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature.* 321:522-5.

Kledal, T.N., M.M. Rosenkilde, F. Coulin, G. Simmons, *et al.* 1997. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. *Science.* 277:1656-9.

Klein, C., J.I. Paul, K. Sauve, M.M. Schmidt, *et al.* 1998. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. *Nat Biotechnol.* 16:1334-7.

Penfold, M.E., D.J. Dairaghi, G.M. Duke, N. Saederup, *et al.* 1999. Cytomegalovirus encodes a potent alpha chemokine. *Proc Natl Acad Sci U S A.* 96:9839-44.

*Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. *Nature.* 332:323-7.

*Rossi, D., and A. Zlotnik. 2000. The Biology of Chemokines and their Receptors. *Annu. Rev. Immunol.* 18:217-242.

Tuerk, C., and L. Gold. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science.* 249:505-10.

*Verhoeyen, M., C. Milstein, and G. Winter. 1988. Reshaping human antibodies: grafting an antilysozyme activity. *Science.* 239:1534-6.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in

connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that 6,451,522 B2 disclosed in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application of the U.S. Serial No. 10/154,399, filed May 22, 2002, as evidenced by the enclosed search report.


Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Magdalena O. Cilella, Ph.D.
Limited Recognition Certificate was filed
on July 30, 2003
Agent of Attorney for Applicants

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



FORM PTO-1449	SERIAL NO. 10/630,180	CASE NO. 10709/47
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE July 30, 2003	GROUP ART UNIT 1645
APPLICANTS: Wei, et al.		

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	6,451,522 B2	09/17/2002	LaRosa, G.		
	A2	2003/0166143 A1	09/04/03	Klein CA, et al.		
	A3	4,816,567				

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A4	* Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, <i>et al.</i> 1987. Current protocols in molecular biology. John Wiley & Sons, New York.
	A5	Bacon, K.B., R.D. Camp, F.M. Cunningham, and P.M. Woollard. 1988. Contrasting in vitro lymphocyte chemotactic activity of the hydroxyl enantiomers of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. <i>Br J Pharmacol.</i> 95:966-74.
	A6	* Baggiolini et al., <i>Annu. Rev. Immunol.</i> 15: 675-705 (1997)
	A7	* Baggiolini et al., <i>Advances in Immunology</i> , 55:97-179 (1994)
	A8	* Deng, et al., <i>Nature</i> , 381:661-666 (1996)
	A9	Ellington, A.D., and J.W. Szostak. 1990. In vitro selection of RNA molecules that bind specific ligands. <i>Nature.</i> 346:818-22.
	A10	Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, <i>et al.</i> 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. <i>Cell.</i> 99:23-33.
	A11	* Horuk, <i>Trends Pharm. Sci.</i> , 15:159-165 (1994)
	A12	* Jayasena, S.D. 1999. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. <i>Clin Chem.</i> 45:1628-50.
	A13	* Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger, <i>et al.</i> 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. <i>Nature.</i> 321:522-5.
	A14	Kledal, T.N., M.M. Rosenkilde, F. Coulin, G. Simmons, <i>et al.</i> 1997. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. <i>Science.</i> 277:1656-9.
	A15	Klein, C., J.I. Paul, K. Sauve, M.M. Schmidt, <i>et al.</i> 1998. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. <i>Nat Biotechnol.</i> 16:1334-7.
	A16	Penfold, M.E., D.J. Dairaghi, G.M. Duke, N. Saederup, <i>et al.</i> 1999. Cytomegalovirus encodes a potent alpha chemokine. <i>Proc Natl Acad Sci U S A.</i> 96:9839-44.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	SERIAL NO. 10/630,180	CASE NO. 10709/47
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE July 30, 2003	GROUP ART UNIT Error! Reference source not found.
APPLICANT(S): Wei, et al.		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A17	* Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. <i>Nature</i> . 332:323-7.
	A18	* Rossi, D., and A. Zlotnik. 2000. The Biology of Chemokines and their Receptors. <i>Annu. Rev. Immunol.</i> 18:217-242.
	A19	Tuerk, C., and L. Gold. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. <i>Science</i> . 249:505-10.
	A20	* Verhoeven, M., C. Milstein, and G. Winter. 1988. Reshaping human antibodies: grafting an antilysozyme activity. <i>Science</i> . 239:1534-6.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.